- Home
- AMN vs GHRS Comparison
AMN vs GHRS Comparison
Compare AMN & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMN
- GHRS
- Stock Information
- Founded
- AMN 1985
- GHRS 2018
- Country
- AMN United States
- GHRS Ireland
- Employees
- AMN N/A
- GHRS N/A
- Industry
- AMN Assisted Living Services
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- AMN Health Care
- GHRS Health Care
- Exchange
- AMN Nasdaq
- GHRS Nasdaq
- Market Cap
- AMN 983.8M
- GHRS 868.7M
- IPO Year
- AMN 2001
- GHRS 2021
- Fundamental
- Price
- AMN $27.59
- GHRS $12.51
- Analyst Decision
- AMN Hold
- GHRS Strong Buy
- Analyst Count
- AMN 8
- GHRS 3
- Target Price
- AMN $44.50
- GHRS $35.67
- AVG Volume (30 Days)
- AMN 1.1M
- GHRS 1.1M
- Earning Date
- AMN 02-20-2025
- GHRS 03-07-2025
- Dividend Yield
- AMN N/A
- GHRS N/A
- EPS Growth
- AMN N/A
- GHRS N/A
- EPS
- AMN N/A
- GHRS N/A
- Revenue
- AMN $2,983,781,000.00
- GHRS N/A
- Revenue This Year
- AMN N/A
- GHRS N/A
- Revenue Next Year
- AMN N/A
- GHRS N/A
- P/E Ratio
- AMN N/A
- GHRS N/A
- Revenue Growth
- AMN N/A
- GHRS N/A
- 52 Week Low
- AMN $22.47
- GHRS $6.00
- 52 Week High
- AMN $70.07
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- AMN 60.85
- GHRS 51.44
- Support Level
- AMN $22.72
- GHRS $13.50
- Resistance Level
- AMN $24.50
- GHRS $14.91
- Average True Range (ATR)
- AMN 1.42
- GHRS 1.58
- MACD
- AMN 0.09
- GHRS -0.22
- Stochastic Oscillator
- AMN 62.68
- GHRS 5.56
About AMN AMN Healthcare Services Inc
AMN Healthcare Services is one of the largest healthcare staffing company in the United States. In 2023, it offered more than 13,000 nurses and allied healthcare full-time workers with provider clients nationwide. About two thirds of its business is generated from its temporary nursing division; the other third is generated from its physician placement and technology-backed workplace solutions divisions.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.